357 related articles for article (PubMed ID: 24853420)
1. Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression.
Chen F; Li A; Gao S; Hollern D; Williams M; Liu F; VanSickle EA; Andrechek E; Zhang C; Yang C; Luo R; Xiao H
Cell Death Dis; 2014 May; 5(5):e1242. PubMed ID: 24853420
[TBL] [Abstract][Full Text] [Related]
2. Tip30 deletion in MMTV-Neu mice leads to enhanced EGFR signaling and development of estrogen receptor-positive and progesterone receptor-negative mammary tumors.
Zhang C; Mori M; Gao S; Li A; Hoshino I; Aupperlee MD; Haslam SZ; Xiao H
Cancer Res; 2010 Dec; 70(24):10224-33. PubMed ID: 21159643
[TBL] [Abstract][Full Text] [Related]
3. RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells.
van Bragt MP; Hu X; Xie Y; Li Z
Elife; 2014 Nov; 3():e03881. PubMed ID: 25415051
[TBL] [Abstract][Full Text] [Related]
4. Deletion of Tip30 leads to rapid immortalization of murine mammary epithelial cells and ductal hyperplasia in the mammary gland.
Pecha J; Ankrapp D; Jiang C; Tang W; Hoshino I; Bruck K; Wagner KU; Xiao H
Oncogene; 2007 Nov; 26(53):7423-31. PubMed ID: 17533366
[TBL] [Abstract][Full Text] [Related]
5. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models.
Melchor L; Molyneux G; Mackay A; Magnay FA; Atienza M; Kendrick H; Nava-Rodrigues D; López-García MÁ; Milanezi F; Greenow K; Robertson D; Palacios J; Reis-Filho JS; Smalley MJ
J Pathol; 2014 Jun; 233(2):124-37. PubMed ID: 24615332
[TBL] [Abstract][Full Text] [Related]
6. FOXA1 represses the molecular phenotype of basal breast cancer cells.
Bernardo GM; Bebek G; Ginther CL; Sizemore ST; Lozada KL; Miedler JD; Anderson LA; Godwin AK; Abdul-Karim FW; Slamon DJ; Keri RA
Oncogene; 2013 Jan; 32(5):554-63. PubMed ID: 22391567
[TBL] [Abstract][Full Text] [Related]
7. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.
Regan JL; Kendrick H; Magnay FA; Vafaizadeh V; Groner B; Smalley MJ
Oncogene; 2012 Feb; 31(7):869-83. PubMed ID: 21765473
[TBL] [Abstract][Full Text] [Related]
8. Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR axis.
Celià-Terrassa T; Liu DD; Choudhury A; Hang X; Wei Y; Zamalloa J; Alfaro-Aco R; Chakrabarti R; Jiang YZ; Koh BI; Smith HA; DeCoste C; Li JJ; Shao ZM; Kang Y
Nat Cell Biol; 2017 Jun; 19(6):711-723. PubMed ID: 28530657
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
10. MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors.
Wan L; Lu X; Yuan S; Wei Y; Guo F; Shen M; Yuan M; Chakrabarti R; Hua Y; Smith HA; Blanco MA; Chekmareva M; Wu H; Bronson RT; Haffty BG; Xing Y; Kang Y
Cancer Cell; 2014 Jul; 26(1):92-105. PubMed ID: 24981741
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
12. Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.
Gastaldi S; Sassi F; Accornero P; Torti D; Galimi F; Migliardi G; Molyneux G; Perera T; Comoglio PM; Boccaccio C; Smalley MJ; Bertotti A; Trusolino L
Oncogene; 2013 Mar; 32(11):1428-40. PubMed ID: 22562252
[TBL] [Abstract][Full Text] [Related]
13. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
14. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
15. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.
Seksenyan A; Kadavallore A; Walts AE; de la Torre B; Berel D; Strom SP; Aliahmad P; Funari VA; Kaye J
BMC Cancer; 2015 Jan; 15():22. PubMed ID: 25632947
[TBL] [Abstract][Full Text] [Related]
16. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
17. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14.
Asselin-Labat ML; Sutherland KD; Vaillant F; Gyorki DE; Wu D; Holroyd S; Breslin K; Ward T; Shi W; Bath ML; Deb S; Fox SB; Smyth GK; Lindeman GJ; Visvader JE
Mol Cell Biol; 2011 Nov; 31(22):4609-22. PubMed ID: 21930782
[TBL] [Abstract][Full Text] [Related]
18. IGF1R constitutive activation expands luminal progenitors and influences lineage differentiation during breast tumorigenesis.
Farabaugh SM; Litzenburger BC; Elangovan A; Pecar G; Walheim L; Atkinson JM; Lee AV
Dev Biol; 2020 Jul; 463(1):77-87. PubMed ID: 32376245
[TBL] [Abstract][Full Text] [Related]
19. STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.
Chan SR; Vermi W; Luo J; Lucini L; Rickert C; Fowler AM; Lonardi S; Arthur C; Young LJ; Levy DE; Welch MJ; Cardiff RD; Schreiber RD
Breast Cancer Res; 2012 Jan; 14(1):R16. PubMed ID: 22264274
[TBL] [Abstract][Full Text] [Related]
20. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Wu J; Crowe DL
Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
